Lipidomics Reveals Early Metabolic Changes in Subjects with Schizophrenia: Effects of Atypical Antipsychotics

• Published in: PloS one Vol. 8; no. 7; p. e68717
• Main Authors: McEvoy, Joseph, Baillie, Rebecca A., Zhu, Hongjie, Buckley, Peter, Keshavan, Matcheri S., Nasrallah, Henry A., Dougherty, George G., Yao, Jeffrey K., Kaddurah-Daouk, Rima
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 24.07.2013; Public Library of Science (PLoS)
• Subjects: Aberration; Adult; Antipsychotic Agents - adverse effects; Antipsychotic Agents - therapeutic use; Antipsychotics; Aripiprazole; Behavioral sciences; Biomarkers; Brain; Comparative analysis; Control; Development and progression; Diabetes; Diagnostic systems; Disease control; Dopamine; Drugs; Fatty acids; Fatty Acids, Omega-3 - metabolism; Fatty Acids, Omega-6 - metabolism; Fatty Acids, Unsaturated - metabolism; Female; Genetic aspects; Glycerylphosphorylcholine - metabolism; Humans; Iron; Laboratories; Lecithin; Lipid metabolism; Lipid Metabolism - drug effects; Lipids; Male; Medical treatment; Mental disorders; Metabolism; Metabolites; Middle Aged; Neurosciences; Patients; Phosphatidylcholine; Phosphatidylethanolamine; Phosphatidylethanolamines - metabolism; Phospholipids; Phospholipids - metabolism; Physiological aspects; Polyunsaturated fatty acids; Psychiatry; Psychosis; Psychotropic drugs; Risperidone; Schizophrenia; Schizophrenia - drug therapy; Schizophrenia - metabolism; Serotonin; Studies; United States; North Carolina; Pittsburgh Pennsylvania; United States > US; Pennsylvania

There is a critical need for mapping early metabolic changes in schizophrenia to capture failures in regulation of biochemical pathways and networks. This information could provide valuable insights about disease mechanisms, trajectory of disease progression, and diagnostic biomarkers. We used a lip...